Tracked deals
9
9 tracked deals across 2020-2026.
Public Company
Healthcare
Novartis
Basel, Basel-Stadt, Switzerland
Innovative medicines company. Reimagines medicine to improve and extend people’s lives, developing and commercializing therapies across multiple therapeutic areas.
- Focus Areas
- Pharmaceuticals, Biotechnology, Oncology
- Website
- www.novartis.com
Recent pace
2
2 tracked deals announced in the last 12 months.
Deal mix
Buyout
9 buyout
Novartis Acquisition Volume by Year
Last 5 years
Actual
Full-year estimate
Supporting Data
Recent Transactions
-
- Buyer
- Novartis
- Target
- Myricx Bio
- Seller
- Sofinnova Partners
- Industry
- Biotechnology
- Location
- United Kingdom
- Type
- Buyout
Sofinnova Partners’ portfolio company Myricx Bio has agreed to be acquired by Novartis in a deal valued at up to $1.5 billion, including $1.1 billion in cash upfront plus potential milestone payments. Myricx Bio is a UK-headquartered biotech developing NMTi payloads and lead ADC assets targeting B7-H3 and HER2 for solid tumors.
-
March 27, 2026
- Buyer
- Novartis
- Target
- Excellergy
- Industry
- Biotechnology
- Location
- California, United States
- Type
- Buyout
Novartis entered into an agreement to acquire Excellergy, a private biotechnology company developing next-generation anti-IgE therapies, in a deal valued at up to $2 billion including upfront and milestone payments. The acquisition will bring Excellergy’s lead asset, Exl-111 (a potentially first-in-class trifunctional effector cell response inhibitor), into Novartis’ allergy and immunology pipeline.
-
June 25, 2025
- Buyer
- Novartis AG
- Target
- Regulus Therapeutics Inc.
- Industry
- Biotechnology
- Location
- California, United States
- Type
- Buyout
Novartis has completed the acquisition of Regulus Therapeutics, making Regulus an indirect wholly owned subsidiary following a tender offer and merger. The deal secures Regulus' investigational oligonucleotide therapy farabursen for ADPKD and strengthens Novartis' renal disease pipeline.
-
May 2, 2024
- Buyer
- Novartis
- Target
- Mariana Oncology
- Industry
- Biotechnology
- Location
- Massachusetts, United States
- Type
- Buyout
Novartis will acquire Mariana Oncology for $1 billion upfront and up to $750 million in milestone payments, bringing Mariana's peptide-based radiopharmaceutical pipeline and manufacturing capabilities into Novartis. The deal adds radioligand therapeutic discovery, isotope supply chain and manufacturing know-how to Novartis to accelerate development and commercialization of targeted cancer therapies.
-
July 17, 2023
- Buyer
- Novartis
- Target
- DTx Pharma
- Industry
- Biotechnology
- Location
- California, United States
- Type
- Buyout
Novartis has acquired DTx Pharma, a San Diego–based preclinical biotechnology company, for an upfront payment of USD 500 million plus contingent milestone payments. The deal brings DTx's FALCON siRNA delivery platform and lead program DTx-1252 (orphan-designated for CMT1A) into Novartis to strengthen its neuroscience pipeline and xRNA capabilities.
-
June 12, 2023
- Buyer
- Novartis AG
- Target
- Chinook Therapeutics, Inc.
- Seller
- Chinook Therapeutics stockholders
- Industry
- Biotechnology
- Location
- Washington, United States
- Type
- Buyout
Novartis AG agreed to acquire Chinook Therapeutics for $40 per share in cash, with contingent value rights of up to $4 per share tied to regulatory milestones —bringing total consideration to as much as approximately $3.5 billion. The acquisition, approved by both companies' boards, brings Chinook's kidney-disease pipeline into Novartis' renal portfolio and was expected to close in the second half of 2023 subject to customary conditions.
-
December 17, 2020
- Buyer
- Novartis
- Target
- Cadent Therapeutics
- Industry
- Biotechnology
- Location
- Massachusetts, United States
- Type
- Buyout
Novartis has entered an agreement to acquire Cadent Therapeutics, a Cambridge, Massachusetts–based clinical‑stage neuroscience company, adding two clinical‑stage programs for schizophrenia and movement disorders plus the buyout of MIJ821 milestones/royalties. The deal (reported up to $770 million including milestones) strengthens Novartis' neuropsychiatry portfolio and is expected to close in Q1 2021 subject to customary conditions.
-
September 30, 2020
- Buyer
- Novartis
- Target
- Vedere Bio, Inc.
- Seller
- Shareholders of Vedere Bio
- Industry
- Biotechnology
- Location
- Massachusetts, United States
- Type
- Buyout
Novartis has acquired Vedere Bio, a Cambridge-based optogenetics AAV gene therapy company, for $150 million upfront plus up to $130 million in potential regulatory and clinical milestones (total consideration of $280 million). The deal includes Vedere Bio's lead preclinical intravitreal AAV programs focused on pan-genotypic vision restoration; earlier-stage assets were spun out into a newly formed independent company, Vedere Bio II.
-
- Buyer
- Novartis
- Target
- Amblyotech
- Industry
- Medical Devices
- Location
- United States
- Type
- Buyout
Novartis has completed the acquisition of Amblyotech, a US-based digital therapeutics software startup, to develop a software-as-a-medical-device (SaMD) for the treatment of amblyopia. Novartis will collaborate with Ubisoft and McGill University to develop engaging games and advance clinical development toward regulatory approval, aiming to expand its ophthalmology digital-therapy capabilities.
Related Acquisition Pages
Biotechnology Buyers & Acquisitions
8 tracked deals by Novartis.
Medical Devices Buyers & Acquisitions
1 tracked deal by Novartis.
Acquisitions in California
3 tracked deals by Novartis.
Acquisitions in Massachusetts
3 tracked deals by Novartis.
Acquisitions in Washington
1 tracked deal by Novartis.
Selling a company? Get in front of buyers like Novartis
Turn tracked acquisition activity into an outreach-ready buyer list.